Releasing pressure in tumors: what do we know so far and where do we go from here? A review.

  title={Releasing pressure in tumors: what do we know so far and where do we go from here? A review.},
  author={A. B. Ariffin and Patrick F. Forde and Saleem Muhammad Jahangeer and D. Soden and John Hinchion},
  journal={Cancer research},
  volume={74 10},
Tumor interstitial pressure is a fundamental feature of cancer biology. Elevation in tumor pressure affects the efficacy of cancer treatment. It causes heterogenous intratumoral distribution of drugs and macromolecules. It also causes the development of hypoxia within tumor bulk, leading to reduced efficacy of therapeutic drugs and radiotherapy. Tumor pressure has been associated with increased metastatic potential and poor prognosis in some tumors. The formation of increased pressure in solid… 

Figures and Tables from this paper

Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy

The intratumoral pressure is reviewed using direct tumor-pressure measurement strategies, such as the wick-in-needle and pressure catheter transducer method, and indirect tumor- pressure measurement strategies via magnetic resonance.

Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid

All the methods (drugs, nutraceuticals, and physical methods of treatment) able to lower TIFP and to modify ECM used for increasing drug concentration within the tumor tissue are described.

Interstitial fluid flow in cancer: implications for disease progression and treatment

The current understanding of the role of interstitial flow in cancer and the tumor microenvironment through cancer progression and therapy is outlined and the current role of fluid flow in the treatment of cancer, including drug transport and therapeutic strategies is discussed.

Vascular and extracellular matrix remodeling by physical approaches to improve drug delivery at the tumor site

Physical approaches to modulate vascular properties and remodel the extracellular matrix are of particular interest to locally control and improve drug delivery and thus increase its therapeutic index.

Tumor Interstitial Fluid Formation, Characterization, and Clinical Implications

The present review discusses available techniques for TIF isolation, results from subsequent characterization and implications of recent findings with respect to fluid filtration and uptake of macromolecular therapeutic agents.

Vascular Normalization, T Cell Trafficking and Anti-tumor Immunity

How T cell trafficking is blunted at the tumor blood vessel interface is discussed and how therapies that are effective in normalizing the tumor vasculature can re-establish T cell infiltration into an inflammatory tumor microenvironment, leading to therapeutic benefits in the cancer setting is discussed.

Hyaluronan: A modulator of the tumor microenvironment.




Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.

Using a mathematical model to simulate IFP and IFV profiles in tumors, it is shown that antiangiogenic therapy can decrease IFP by decreasing the tumor size, vascular hydraulic permeability, and/or the surface area per unit tissue volume of tumor vessels.

Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors.

Clonogenic cell survival data indicated that ZD6126 was less effective in tumors with high IFP values (>25 mm Hg), which may reflect greater microregional blood flow limitations in these tumors and reduced access of the drug to the target endothelial cells.

Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models.

Induction of a thermoregulatory-mediated increase in tissue blood flow, induced by exposure of mice to mild environmental heat stress, could influence IFP and other vascular parameters within tumors, suggesting, for the first time, that environmental manipulation of normal vasomotor function is capable of achieving therapeutically beneficial changes in IFP in the tumor microenvironment.

Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft.

The goals of this study were to find the minimum dose of radiation required to modulate IFP and pO(2) and to determine the time course of IFP changes due to radiation in a preclinical model and to identify the radiation-induced decrease in IFP that could be responsible for the increased uptake of monoclonal antibodies following single or fractionated radiation.

Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors

It is demonstrated that blocking vascular endothelial growth factor signaling by DC101 (a VEGF-receptor-2 antibody) decreases interstitial fluid pressure, not by restoring lymphatic function, but by producing a morphologically and functionally “normalized” vascular network.

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11

It is suggested that tumour vascular function and tumour uptake of anticancer drugs improve with VEGF-blocking therapy, and the relevance for further investigations is indicated.

Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response.

The association of an enhanced biological effect with a more pronounced reduction of interstitial fluid pressure suggests that the IFP might serve as a quantitative parameter to predict the response of tumors to hyperthermic therapy.

Irradiation reduces interstitial fluid transport and increases the collagen content in tumors.

It is shown that the interstitial diffusion of large molecules is significantly hindered in tumors with high collagen levels, and after irradiation, the decrease in K and increase in collagen type I levels could significantly hinder the convective movement and diffusion ofLarge therapeutic agents in tumors.

Vascular damaging agents.

  • D. PattersonG. Rustin
  • Biology, Medicine
    Clinical oncology (Royal College of Radiologists (Great Britain))
  • 2007